LifeSci Public Relations

New technology shows potential to improve potency and durability benefits in gene therapy

Researchers have developed an immune tolerance platform called ImmTORTM to overcome challenges in gene therapy, including immunogenicity and durability. The addition of ImmTOR nanoparticles to AAV vectors has shown potential to enhance efficacy, safety, and durability by mediating more efficient transgene expression.

SourceLifeSci Public Relations·JournalJournal of Mathematical Sciences Advances and Applications·DateFeb 24, 2021

SQZ cell engineering technology shows key advantages for developing cell therapies

The SQZ Biotechnologies platform has been shown to preserve key biological functions essential for cell therapies, unlike electroporation technology. This study highlights the superiority of SQZ in delivering target-specific immune responses and enabling scalable cell therapy development.

SourceLifeSci Public Relations·JournalProceedings of the National Academy of Sciences·DateNov 1, 2018

Arrowhead data reveal important considerations for future hepatitis B treatment

New study reveals integrated HBV DNA as a significant source of HBsAg, expanding understanding of HBV biology and host interactions. The findings have important implications for future trial design and endpoint expectations for new therapies developed to cure chronic HBV.

SourceLifeSci Public Relations·JournalScience Translational Medicine·DateSep 27, 2017